Castle Biosciences reports preliminary FY23 revenue $210M, consensus $203.95M

Says it delivered 20,284 total test reports in Q4, compared to 12,644 in the same period of 2022, an increase of 60%. Says total test reports delivered in 2023 were 70,429, compared to 44,419 in the same period of 2022, an increase of 59%. Year-end 2023 cash and cash equivalents are expected to be approximately $99M. Additionally, the company expects to hold approximately $144M in short-term investments.